Business Wire

Hytera Hosts a Successful Global Partner Summit 2023 in Bali, Indonesia

15.5.2023 13:54:00 EEST | Business Wire | Press release

Share

Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, gathered its distribution, project, and application partners from over 50 countries and regions and successfully held Hytera Global Partner Summit (HGPS) 2023 on May 11th in Bali, Indonesia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005390/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yelin Jiang, CEO of Hytera Group, delivering the keynote speech (Photo: Business Wire)

HGPS serves as a platform for Hytera partners to network with other like-minded professionals, gain insights into the latest trends of the industry, and learn what’s new with Hytera, including new products, solutions, and policies. The year 2023 marks the 30th anniversary of the company; therefore, HGPS 2023 was also a venue for the retrospect and celebration of the common journey shared by Hytera and its partners from across the world.

“The past 30 years have seen Hytera rose against numerous challenges and evolved from a product provider to a technology and solution provider. Now we are one of the leading companies in mission-critical and business-critical communications. Our talented engineers working in 8 R&D facilities across the world are the source of our confidence in future growth,” said Yelin Jiang, CEO of Hytera Group, in the keynote speech. “In 2022, Hytera released many innovative new products across multiple product series such as DMR radios , MCS & PoC radios, and body cameras. The new-generation H Series DMR radio was an instant success in the market.”

Thomas Lynch, executive research director of Omdia, was present to share the latest industry trends and developments with attendees, providing insights into the ever-changing industry landscape. According to Omdia’s analysis, in response to the market demands for data-rich features, Mission Critical Communications are moving towards a hybrid approach: keeping trusted LMR technology, such as TETRA, DMR, PDT for the indispensable voice communication in extreme situations and empowering the additional services and features with integrated LTE Broadband solutions. This is manifested in Hytera’s multi-front product development strategy.

Fully leveraging the venue of HGPS, Hytera brought regional partners into a global perspective with product solution deep dives and partners’ case studies. At the exhibition area, a complete portfolio of Hytera products and solutions were showcased, including TETRA Radios and Systems, DMR Radios and Systems, MCS & PoC Radios and Solutions , Body Camera Solutions , Multimedia Communication Platform, Control Room Solutions, 4G&5G Systems, and Fast Deployment Solutions. HGPS2023 invited some of Hytera ecosystem partners to showcase their value-added applications on top of Hytera products and they brought solutions such as encryptions, dispatching, satellite connectivity, and emergency coordination.

The Summit concluded on a high note with the Hytera 30th Anniversary and Awarding Ceremony, which acknowledged the performance and progress of partners in the year 2022. Golden Loyalty Awards was specially set up for HGPS2023 to celebrate the long-term partnership with and loyalty to the Hytera brand in the past three decades.

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

lele.yao@hytera.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye